653 related articles for article (PubMed ID: 26810324)
1. Quality of life in patients with lower urinary tract symptoms associated with BPH: change over time in real-life practice according to treatment--the QUALIPROST study.
Alcaraz A; Carballido-Rodríguez J; Unda-Urzaiz M; Medina-López R; Ruiz-Cerdá JL; Rodríguez-Rubio F; García-Rojo D; Brenes-Bermúdez FJ; Cózar-Olmo JM; Baena-González V; Manasanch J
Int Urol Nephrol; 2016 May; 48(5):645-56. PubMed ID: 26810324
[TBL] [Abstract][Full Text] [Related]
2. Can we use baseline characteristics to assess which men with moderately symptomatic benign prostatic hyperplasia at risk of progression will benefit from treatment? A post hoc analysis of data from the 2-year CONDUCT study.
Roehrborn CG; Oyarzabal Perez I; Roos EP; Calomfirescu N; Brotherton B; Palacios JM; Vasylyev A; Manyak MJ
World J Urol; 2017 Mar; 35(3):421-427. PubMed ID: 27334136
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
[TBL] [Abstract][Full Text] [Related]
4. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
5. [Alpha-blockers or hexanic extract of Serenoa repens for 6 months: sub-analysis of the PERSAT study].
de la Taille A; Chalret du Rieu Q; Dialla O; Bardin L
Prog Urol; 2023 Feb; 33(2):66-72. PubMed ID: 36207246
[TBL] [Abstract][Full Text] [Related]
6. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
7. Effects of hexanic extract of Serenoa repens (Permixon® 160 mg) on inflammation biomarkers in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.
Latil A; Pétrissans MT; Rouquet J; Robert G; de la Taille A
Prostate; 2015 Dec; 75(16):1857-67. PubMed ID: 26306400
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Tolerability of 6-Month Treatment with Tamsulosin Plus the Hexanic Extract of
Alcaraz A; Castro-Díaz D; Gacci M; Salonia A; Ficarra V; Carballido-Rodríguez J; Rodríguez-Antolín A; Medina-Polo J; Fernández-Gómez JM; Cózar-Olmo JM; Búcar-Terrades S; Pérez-León N; Brenes-Bermúdez FJ; Molero-García JM; Fernández-Pro-Ledesma A; Herdman M; Angulo JC; Manasanch J; On Behalf Of The Qualiprost Study Group
J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806900
[TBL] [Abstract][Full Text] [Related]
9. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Hwang EC; Gandhi S; Jung JH; Imamura M; Kim MH; Pang R; Dahm P
Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007360. PubMed ID: 30306544
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of the hexanic extract of Serenoa repens compared to tamsulosin in moderate-severe LUTS-BPH patients.
Alcaraz A; Rodríguez-Antolín A; Carballido-Rodríguez J; Castro-Díaz D; Medina-Polo J; Fernández-Gómez JM; Ficarra V; Palou J; Ponce de León Roca J; Angulo JC; Esteban-Fuertes M; Cózar-Olmo JM; Pérez-León N; Molero-García JM; Fernández-Pro Ledesma A; Brenes-Bermúdez FJ; Manasanch J
Sci Rep; 2021 Sep; 11(1):19401. PubMed ID: 34588509
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized, open-label, parallel trial comparing the efficacy of α-blocker or 5α-reductase inhibitor withdrawal to continued combination therapy on the maintenance of lower urinary tract symptoms in men with benign prostatic hyperplasia.
Lee KS; Yoo JW; Kim DH; Jeon S; Yang J; Chung BH; Koo KC
Prostate; 2024 Mar; 84(4):403-413. PubMed ID: 38149792
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
13. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.
Fourcade RO; Lacoin F; Rouprêt M; Slama A; Le Fur C; Michel E; Sitbon A; Cotté FE
World J Urol; 2012 Jun; 30(3):419-26. PubMed ID: 21892656
[TBL] [Abstract][Full Text] [Related]
14. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.
Garimella PS; Fink HA; Macdonald R; Wilt TJ
Cochrane Database Syst Rev; 2009 Oct; (4):CD007360. PubMed ID: 19821408
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes of withdrawing one medication from long-term combination therapy comprising α-blocker and 5α-reductase inhibitor for benign prostatic hyperplasia.
Choi JD; Yoo TK; Kang JY; Jung HD; Lee JH
Int Urol Nephrol; 2023 Apr; 55(4):845-851. PubMed ID: 36763223
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
17. Clinical Benefit of Tamsulosin and the Hexanic Extract of Serenoa Repens, in Combination or as Monotherapy, in Patients with Moderate/Severe LUTS-BPH: A Subset Analysis of the QUALIPROST Study.
Alcaraz A; Rodríguez-Antolín A; Carballido-Rodríguez J; Castro-Díaz D; Esteban-Fuertes M; Cózar-Olmo JM; Ficarra V; Medina-López R; Fernández-Gómez JM; Angulo JC; Medina-Polo J; Brenes-Bermúdez FJ; Molero-García JM; Fernández-Pro-Ledesma A; Manasanch J; The Qualiprost Study Group OBO
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32917008
[TBL] [Abstract][Full Text] [Related]
18. Clinical Effects of Oral Supplementation of Gamma-Cyclodextrin Curcumin Complex in Male Patients with Moderate-To-Severe Benign Prostatic Hyperplasia-Related Lower Urinary Tract Symptoms.
Crocerossa F; Cantiello F; Bagalá L; Sicoli F; Carbonara U; Manfredi C; Falagario U; Veccia A; Pandolfo SD; Napolitano L; Ferro M; Di Dio M; Mondaini N; Damiano R
Urol Int; 2023; 107(10-12):924-934. PubMed ID: 37939691
[TBL] [Abstract][Full Text] [Related]
19. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 2-year data from the CombAT trial.
Barkin J; Roehrborn CG; Siami P; Haillot O; Morrill B; Black L; Montorsi F;
BJU Int; 2009 Apr; 103(7):919-26. PubMed ID: 19239460
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD010060. PubMed ID: 30480763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
